Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development expense	$ 18,852	$ 21,697
General and administrative expense	5,605	7,233
Total operating expenses	24,457	28,930
Loss from operations	(24,457)	(28,930)
Other income:
Interest income	1,223	1,480
Other income	0	(10)
Total other income	1,223	1,470
Net loss and comprehensive loss	$ (23,234)	$ (27,460)
Net loss per common share, basic	$ (0.48)	$ (0.58)
Net loss per common share, diluted	$ (0.48)	$ (0.58)
Weighted-average shares of common stock outstanding, basic	48,087,460	47,578,418
Weighted-average shares of common stock outstanding, diluted	48,087,460	47,578,418